Yubing Wang | Oncology | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Yubing Wang | Oncology | Best Researcher Award

Weifang No.2 People’s Hospital | China

AUTHOR PROFILE

Scopus

🔬 EARLY ACADEMIC PURSUITS

Yubing Wang embarked on his academic journey with a strong foundation in biosciences. In 2007, he earned his Bachelor’s degree in Bioscience from Shandong University, which laid the groundwork for his future endeavors in the field of biological and medical sciences. His passion for scientific research led him to pursue further studies, culminating in a Doctor of Science degree from The Chinese University of Hong Kong in 2017. This rigorous academic training provided him with expertise in advanced biological sciences and research methodologies, setting the stage for his future contributions to medical and bioscience research.

🏥 PROFESSIONAL ENDEAVORS

Dr. Wang’s professional career is marked by significant roles in both research and academia. His journey began as a Research Assistant at the Shanghai Institutes for Biological Sciences, CAS, where he worked for six years (2007–2013), gaining hands-on experience in cutting-edge biological research. Following this, he transitioned into academia, taking on the role of Associate Professor at Shandong Second Medical University from 2018 to 2023. His commitment to teaching and research was further recognized when he joined Weifang No.2 People’s Hospital as an Associate Professor in 2023, where he continues to contribute to the advancement of medical sciences.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY

Dr. Wang’s research is centered around biosciences and medical applications, particularly in biological mechanisms and therapeutic developments. His work has contributed to a deeper understanding of biomedical sciences, with a focus on improving clinical outcomes through innovative research. His interdisciplinary approach combines molecular biology, biotechnology, and clinical applications, addressing critical medical challenges and advancing healthcare solutions.

🌍 IMPACT AND INFLUENCE

Throughout his career, Dr. Wang has played a pivotal role in bridging the gap between fundamental bioscience research and its practical applications in medicine. His work has influenced both the academic community and clinical practices, contributing to the development of novel medical treatments and diagnostic tools. By mentoring students and collaborating with fellow researchers, he has fostered a new generation of scientists committed to pushing the boundaries of medical research.

📖 ACADEMIC CITATIONS AND RECOGNITION

Dr. Wang’s research has been widely recognized in the academic community, with numerous scientific publications in reputed journals. His work has been cited by fellow researchers, reflecting the significance and impact of his contributions to biosciences and medical research. His research has also been instrumental in guiding clinical practices and informing new treatment methodologies.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

As an esteemed academic and researcher, Dr. Wang continues to expand his influence in bioscience and medical research. His future endeavors aim to enhance interdisciplinary research collaborations, further the development of innovative healthcare solutions, and mentor the next generation of scientists and medical professionals. His work at Weifang No.2 People’s Hospital is expected to drive forward transformative research, ultimately improving patient care and advancing medical knowledge.

🏆 CONCLUSION

Dr. Yubing Wang’s career exemplifies a commitment to scientific excellence, academic mentorship, and transformative medical research. His contributions in biosciences and medicine have left a lasting impact on both academia and clinical practice. With his expertise and dedication, he continues to shape the future of biomedical research, paving the way for groundbreaking discoveries and improved healthcare outcomes. His legacy as a researcher and educator ensures that his influence will be felt for generations to come.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer
    Authors: B., Yang, Ben , R., Kou, Rongguan , H., Wang, Hui , … W., Yu, Wenjing , Z., Gao, Zhiqin
    Journal: International Journal of Molecular Medicine
    Year: 2024

 

  1. Title: Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway
    Authors: L., Guo, Li , S., Zhang, Sai , C., Zhang, Cong , … Y., Gao, Yuanyuan , T., Sun, Tongyi
    Journal: International Immunopharmacology
    Year: 2024

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Qufu Normal University | China

AUTHOR PROFILE

Scopus

Google Scholar

🏫 EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Feng Li began their academic journey with a solid foundation in the life sciences, focusing on biology and computational biology during their undergraduate and graduate studies. They earned advanced degrees specializing in bioinformatics and oncology-related research, which positioned them at the intersection of biological data analysis and tumor research. Their early years were marked by exceptional performance, earning scholarships and accolades for academic excellence.

💼 PROFESSIONAL ENDEAVORS

Dr. Feng Li currently serves as an Associate Professor at Qufu Normal University in China. They have built a career that bridges teaching, research, and mentorship, shaping the next generation of scientists in the field of tumor biology and bioinformatics. They also collaborate with leading researchers and institutions, contributing to multidisciplinary projects and promoting innovation in their field.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Dr. Li’s primary research focus lies in tumor biology, particularly the application of bioinformatics to understand cancer mechanisms. Their work emphasizes:

  • Identifying biomarkers for cancer diagnostics and therapy.
  • Analyzing genomic and proteomic data to uncover tumor-related pathways.
  • Developing predictive models for patient outcomes using machine learning.

Their groundbreaking research has led to the publication of numerous peer-reviewed articles, advancing knowledge in cancer genomics and computational oncology.

🌍 IMPACT AND INFLUENCE

Through their research, Dr. Feng Li has significantly impacted the scientific community by:

  • Enhancing the understanding of cancer biology.
  • Introducing innovative bioinformatics tools for data analysis.
  • Influencing clinical practices with actionable insights from their studies.

Their work is frequently cited, reflecting their contributions to the broader academic discourse in oncology and bioinformatics.

📊 ACADEMIC CITES

Dr. Li’s publications have garnered widespread recognition, with a growing H-index reflecting their influence in the academic community. Their articles are cited by researchers worldwide, signifying the value and relevance of their findings.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Feng Li’s legacy is marked by their dedication to advancing cancer research and mentoring young scientists. Looking ahead, their focus includes:

  • Expanding research in personalized cancer therapies.
  • Fostering collaborations between bioinformatics and clinical oncology.
  • Inspiring future generations through teaching and research initiatives.

🌟 OTHER IMPORTANT TOPICS

  • Teaching Excellence: Dr. Li is recognized for their engaging teaching methods, integrating real-world research into classroom learning.
  • Community Engagement: Actively participates in academic conferences and workshops, sharing their expertise and fostering knowledge exchange.
  • Interdisciplinary Approach: Their work exemplifies how bioinformatics and oncology can converge to solve complex medical challenges.

🌟CONCLUSION 

Assoc. Prof. Dr. Feng Li has emerged as a pivotal figure in the fields of tumor biology and bioinformatics, blending academic rigor with innovative research to tackle some of the most pressing challenges in oncology. Through their groundbreaking contributions, impactful teaching, and dedication to interdisciplinary collaboration, Dr. Li has left an indelible mark on the scientific community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. SLGCN: Structure-enhanced line graph convolutional network for predicting drug–disease associations
    • Authors: Liu, B.-M., Gao, Y.-L., Li, F., Zheng, C.-H., Liu, J.-X.
    • Journal: Knowledge-Based Systems
    • Year: 2024

    2. A framework for scRNA-seq data clustering based on multi-view feature integration

    • Authors: Li, F., Liu, Y., Liu, J., Ge, D., Shang, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

    3. KFDAE: CircRNA-Disease Associations Prediction Based on Kernel Fusion and Deep Auto-Encoder

    • Authors: Kang, W.-Y., Gao, Y.-L., Wang, Y., Li, F., Liu, J.-X.
    • Journal: IEEE Journal of Biomedical and Health Informatics
    • Year: 2024

    4. Multi-Affinity network integration based on multi-omics data for tumor stratification

    • Authors: Li, F., Gao, Y., Sun, Z., Shang, J., Liu, J.-X.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2025

    5. A review: simulation tools for genome-wide interaction studies

    • Authors: Shang, J., Xu, A., Bi, M., Li, F., Liu, J.-X.
    • Journal: Briefings in Functional Genomics
    • Year: 2024

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Shaanxi Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

💊 WANG PENGCHONG: ACADEMIC PROFILE AND ACHIEVEMENTS 🎓

🎓EARLY ACADEMIC PURSUITS 📚

Wang Pengchong, the Chief Pharmacist at Shaanxi Provincial People’s Hospital, earned his PhD in Pharmacy from Xi’an Jiaotong University. His academic journey was shaped by a focus on tumor pharmacy and targeted drug delivery systems. His early years were spent delving into the intricacies of pharmaceutical care, particularly in the context of oncology, laying the foundation for his future breakthroughs.

💼 PROFESSIONAL ENDEAVORS 🏥

Wang is a dedicated member of the Pharmaceutical Care Committee of the Shaanxi Pharmacological Society. His professional work has revolved around tumor pharmacology, pioneering approaches to targeted cancer treatments. He has played an instrumental role in several major projects, including three general projects funded by the National Natural Science Foundation of China and two key R&D projects in Shaanxi Province. His leadership in high-profile initiatives highlights his influence on pharmaceutical advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS 🎯

Wang Pengchong’s research is centered on targeted drug delivery systems and tumor pharmacy research. His contributions are geared toward improving cancer therapies by focusing on precision medicine, which minimizes side effects and enhances the effectiveness of treatment. His work extends into innovative methods, such as nanotechnology in drug targeting. Wang has led multiple significant projects, including the Shaanxi Province Science and Technology Plan Project, the Xi’an City Science and Technology Plan Project, and the Yaodong Shenzhou Pharmaceutical Research Capacity Building Project.

✨ IMPACT AND INFLUENCE 🌐

Wang’s research has had a profound impact on cancer treatment strategies and pharmaceutical care. His efforts have advanced both the scientific understanding and practical application of cancer drugs, particularly in how they can be precisely targeted to tumor cells while sparing healthy tissues. Through his leadership in government-backed research initiatives, Wang has become a driving force in the field, influencing not just Shaanxi Province but the broader pharmaceutical landscape.

📊 ACADEMIC CITES 📄

In the past five years, Wang Pengchong has published more than ten SCI-indexed papers in international journals. His work is widely cited, particularly in oncology and pharmaceutical sciences. His research topics span from cutting-edge drug delivery systems to therapeutic advancements, solidifying his reputation in the global scientific community.

🌍 LEGACY AND FUTURE CONTRIBUTIONS 🏆

Wang Pengchong’s legacy will continue to grow as he contributes to targeted cancer therapies and pharmaceutical innovations. His role in advancing precision medicine ensures that his work will influence the next generation of cancer treatments. By leading critical projects and setting new benchmarks in oncology pharmacy, Wang is shaping the future of drug delivery systems and cancer care. His ongoing commitment to pharmaceutical research guarantees that his contributions will leave a lasting impact on the field.

📈 CONCLUSION 🌟

Wang Pengchong’s distinguished career as a Chief Pharmacist and researcher has made significant strides in the fields of targeted drug delivery systems and tumor pharmacy. His academic foundation, coupled with leadership in high-impact research projects, has not only advanced cancer treatment but also positioned him as a key contributor to pharmaceutical sciences. With over a decade of impactful publications and successful project leadership, Wang’s research continues to shape the future of oncology treatments, fostering innovations that will benefit patients worldwide. His work embodies a lasting legacy of precision medicine and cutting-edge cancer therapies, ensuring he remains a pivotal figure in pharmaceutical research and development. 🌍🔬

 

📊🔬NOTABLE PUBLICATION:

 

    • Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis
      • Authors: Yan, Y., Sun, Y., Wang, P., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2020

     

    • An improved synthesis of water-soluble dual fluorescence emission carbon dots from holly leaves for accurate detection of mercury ions in living cells
      • Authors: Wang, P., Yan, Y., Zhang, Y., Xing, J., Dong, Y.
      • Journal: International Journal of Nanomedicine
      • Year: 2021

     

    • One-pot synthesis of nuclear targeting carbon dots with high photoluminescence
      • Authors: Wang, P., Ji, H., Guo, S., Xing, J., Dong, Y.
      • Journal: Chinese Chemical Letters
      • Year: 2021

     

    • Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis
      • Authors: Wang, P., Zhang, Y., Lei, H., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2023

     

    • Multifunctional nanosystems sequentially regulating intratumor Fenton chemistry by remodeling the tumor microenvironment to reinforce chemodynamic therapy
      • Authors: Dong, K., Chen, W., Zhao, Z., Lu, T., Dong, Y.
      • Journal: Biomaterials Advances
      • Year: 2022

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Posted on by Pencis

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario Rodríguez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023